Modulation of Ovarian Structure and Abdominal Obesity in Curcumin- and Flutamide-treated Aging FSH-R Haploinsufficient Mice

Abstract

We have previously shown that follicle-stimulating hormone receptor haploinsufficient mice undergo early reproductive senescence with alterations in ovarian structures. The objective of this study was to treat aging (7-8 months) +/— follicle-stimulating hormone receptor mice that are destined for reproductive failure with 2 selected antiandrogens, curcumin and flutamide, to counteract deleterious effects of mild hyperandrogenemia on the ovary and metabolism. Both compounds significantly downregulated the expression of ovarian androgen receptor protein and simultaneously reduced cyclooxygenase 2 protein in the ovary. Immunolocalization of bone morphogenetic protein-15 in the ovary was enhanced considerably by curcumin and partially by flutamide in treated mice. Improved structural changes were evident in zona pellucida of curcumin-treated ovaries. Flutamide reduced p450c-17 (cyp-17 protein) enzyme expression in thecal/interstitial cells, whereas increased expression of 3β-hydroxysteroid dehydrogenase in thecal cells and granulosa-lutein cells of big follicles was apparent in curcumin-treated ovaries. Reduction in abdominal adiposity was greater in flutamide-treated mice. Taken together, our study allows the following conclusions: changes in ovarian histology and oocyte components as well as adipose tissue indicate the potential for reversing ovarian decline and metabolism because of mild hyperandrogenemia that occurs with aging in follicle-stimulating hormone receptor haploinsufficienct mice.

Keywords

Aging ovary androgen excess antiandrogens ovarian structure obesity.

Get full access to this article

View all access options for this article.

References

Rowe T. Fertility and a woman's age. J Reprod Med. 2006;51:157-163.

Tarlatzis BC , Zepiridis L. Perimenopausal conception. Ann N Y Acad Sci. 2003;997:93-104.

Scheen AJ Diabetes mellitus in the elderly: insulin resistance and/or impaired insulin secretion? Diabetes Metab. 2005; 31:5S27-5S34.

Livingstone C. , Collison M. Sex steroids and insulin resistance. Clin Sci (Lond). 2002;102:151-166.

Foth D. , Romer TH Postmenopausal hyperandrogenemia (android obesity, insulin resistance, diabetes mellitus) and therapeutic consequences. In: Fischl FH , ed. Hormone Replacement Therapy Through the Ages, New Cognition and Therapy Concepts: Menopause Andropause. Austria: Krause & Pachernegg GmbH; 2001;159-163.

Wajchenberg BL Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000; 21:697-738.

Ehrmann DA Polycystic ovary syndrome. N Engl J Med. 2005 ;352:1223-1236.

Dierich A. , Sairam MR , Monaco L. , et al. Impairing follicle-stimulating hormone (FSH) signaling in vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. Proc Natl Acad Sci U S A. 1998;95: 13612-13617.

Danilovich N. , Roy I. , Sairam MR Ovarian pathology and high incidence of sex cord tumors in follitropin receptor knockout (FORKO) mice. Endocrinology. 2001;142:3673-3684.

10.

Tiwari-Pandey R. , Yang Y. , Aravindakshan J. , Sairam MR Normalization of hormonal imbalances, ovarian follicular dynamics and metabolic effects in follitrophin receptor knockout mice. Mol Hum Reprod. 2007;13:287-297.

11.

Danilovich N. , Sairam MR Haploinsufficiency of the follicle-stimulating hormone receptor accelerates oocyte loss inducing early reproductive senescence and biological aging in mice. Biol Reprod. 2002;67:361-369.

12.

Danilovich N. , Javeshghani D. , Xing W. , Sairam MR Endocrine alterations and signaling changes associated with declining ovarian function and advanced biological aging in FSH receptor haploinsufficient mice. Biol Reprod. 2002;67: 370-378.

13.

Dorai T. , Gehani N. , Katz A. Therapeutic potential of curcumin in human prostate cancer-I. curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells. Prostate Cancer Prostatic Dis. 2000 ;3:84-93.

14.

Nakamura K. , Yasunaga Y. , Segawa T. , et al. Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int J Oncol . 2002;21:825-830.

15.

Shishodia S. , Sethi G. , Aggarwal BB Curcumin: getting back to the roots. Ann N Y Acad Sci. 2005;1056:206-217.

16.

Soni KB , Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol. 1992;36:273-275.

17.

Egan ME , Pearson M. , Weiner SA , et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science. 2004;304:600-602.

18.

Goldspiel BR , Kohler DR Flutamide: an antiandrogen for advanced prostate cancer. DICP, Ann Pharmacother. 1990;24:616-623.

19.

Moghetti P. Use of antiandrogens as therapy for women with polycystic ovary syndrome. Fertil Steril. 2006;86(suppl 1):S30-S31.

20.

Yang Y. , Balla A. , Danilovich N. , Sairam MR Developmental and molecular aberrations associated with deterioration of oogenesis during complete or partial follicle-stimulating hormone receptor deficiency in mice. Biol Reprod. 2003; 69:1294-1302.

21.

Ormsbee HS III , Ryan CF Production of hypertension with desoxycorticorticosterone acetate-impregnated silicone rubber implants. J Pharm Sci . 1973;62:255-257.

22.

Odot J. , Albert P. , Carlier A. , Tarpin M. , Devy J. , Madoulet C. In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells . Int J Cancer. 2004;111:381-387.

23.

Hsueh EC , Gupta RK , Lefor A. , Reyzin G. , Ye W. , Morton DL Androgen blockade enhances response to melanoma vaccine. J Surg Res. 2003;110:393-398.

24.

Balla A. , Danilovich N. , Yang Y. , Sairam MR Dynamics of ovarian development in the FORKO immature mouse: structural and functional implications for ovarian reserve. Biol Reprod. 2003;69:1281-1293.

25.

Galloway SM , McNatty KP , Cambridge LM , et al. Mutations in an oocyte-derived growth factor gene (BMP15) cause increased ovulation rate and infertility in a dosage-sensitive manner. Nat Genet. 2000;25:279-283.

26.

Bogovich K. , Richards JS Androgen biosynthesis in developing ovarian follicles: evidence that luteinizing hormone regulates thecal 17 alpha-hydroxylase and C17-20-lyase activities. Endocrinology. 1982;111:1201-1208.

27.

Simpson ER , MacDonald PC Endocrine physiology of the placenta. Annu Rev Physiol. 1981;43:163-188.

28.

Hild-Petito S. , West NB , Brenner RM , Stouffer RL Localization of androgen receptor in the follicle and corpus luteum of the primate ovary during the menstrual cycle. Biol Reprod. 1991;44:561-568.

29.

Klimp AH , Hollema H. , Kempinga C. , van der Zee AG , de Vries EG , Daemen T. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res . 2001;61:7305-7309.

30.

Chen X. , Aravindakshan J. , Yang Y. , Sairam MR Early alterations in ovarian surface epithelial cells and induction of ovarian epithelial tumors triggered by loss of FSH receptor. Neoplasia . 2007;9:521-531.

31.

Olefsky JM , Reaven GM Effects of age and obesity on insulin binding to isolated adipocytes. Endocrinology. 1975;96: 1486-1498.

32.

Sairam MR , Wang M. , Danilovich N. , Javeshghani D. , Maysinger D. Early obesity and age-related mimicry of metabolic syndrome in female mice with sex hormonal imbalances. Obesity (Silver Spring) . 2006;14:1142-1154.

33.

Carmina E. The spectrum of androgen excess disorders. Fertil Steril. 2006;85:1582-1585.

34.

Di Pasquale E. , Beck-Peccoz P. , Persani L. Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am J Hum Genet. 2004;75:106-111.

35.

Lenz S. , Pohland R. , Becker F. , Vanselow J. Expression of the bovine aromatase cytochrome P450 gene (Cyp19) is primarily regulated by promoter 2 in bovine follicles and by promoter 1.1 in corpora lutea. Mol Reprod Dev. 2004;67: 406-413.

36.

Gonzalez F. , Rote NS , Minium J. , Kirwan JP Increased activation of nuclear factor kappaB triggers inflammation and insulin resistance in polycystic ovary syndrome . J Clin Endocrinol Metab. 2006;91:1508-1512.

37.

Narayanan BA , Narayanan NK , Davis L. , Nargi D. RNA interference-mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor . Mol Cancer Ther. 2006;5:1117-1125.

38.

Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: preclinical basis . Am J Clin Oncol. 2003;26: S66-S69.

39.

Yamamoto K. , Arakawa T. , Ueda N. , Yamamoto S. Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem . 1995;270:31315-31320.

40.

Risch HA Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst . 1998;90:1774-1786.

41.

Ross R. , Freeman J. , Hudson R. , Janssen I. Abdominal obesity, muscle composition, and insulin resistance in premenopausal women. J Clin Endocrinol Metab. 2002;87:5044-5051.

42.

Gambineri A. , Pelusi C. , Genghini S. , et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2004;60:241-249.

43.

Diamanti-Kandarakis E. , Mitrakou A. , Raptis S. , Tolis G. , Duleba AJ The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome . J Clin Endocrinol Metab. 1998;83:2699-2705.

44.

Li HL , Liu C. , de Couto G. , et al. Curcumin prevents and reverses murine cardiac hypertrophy. J Clin Invest. 2008; 118:879-893.